BEVERLY, Mass., Dec 5 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST(TM) - Progesterone VGS 400 mg vaginal suppository. It is the newest addition, and completes its Progesterone Vaginal Suppository Unit- of-Use Prescription Compounding Kit product line, which already includes FIRST(TM) - Progesterone VGS 25, 50, 100, and 200. The kits are made for one patient and include pre-weighed progesterone, and suppository base, and a unique, patent pending disposable suppository mold for preparation, dispensing, and storage of the suppositories, all in one unit that increases patient compliance, and ease of use.
"With the launch of FIRST(TM) - Progesterone VGS 400, physicians now have a complete range of FIRST(TM) compounded progesterone suppositories to offer their patients," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc.
FIRST(TM) products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST(TM) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared in the conventional way using a metal suppository mold or polystyrene shells. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.
CutisPharma currently has nine proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages. FIRST(TM) Unit-of- Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
About CutisPharma
CutisPharma, Inc. based in Beverly, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. A U.S. patent has been issued to the Company and additional patents are pending.
For more information please visit our website at www.cutispharma.com
CutisPharma, Inc.CONTACT: James Nagle, V.P. Business Development for CutisPharma, Inc.,+1-978-867-1010 x20
Web site: http://www.cutispharma.com/
